Nuclear terrorism prevention

Von Hippel, Frank, Recommendations for Preventing Nuclear Terrorism, Federation of American Scientists, Public Interest Report, Washington, D.C. Federation of American Scientists, November/December 2001. 

Carson, M.J., Taylor, T., Eyster, E., Maraman, W. and Weshsler, J., Can terrorists build nuclear weapons In P. Leventhal and Y. Alexander (eds.). Preventing Nuclear Terrorism. Lexington Books, Massachusetts, 1987. 

The CPPNM, which was opened for signature in 1980 and which entered into force in 1987, reflects a three-pronged approach" that characterizes the international law related to nuclear security prevention of nuclear terrorism through... 

Ricin and Proteins The threat of a nuclear attack is one reason that Congress established the bipartisan Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism in 2007. In December 2008, the Commission issued World at Risk, a report that cautions that a weapon of mass destruction is likely to be used somewhere in the world before the end of 2013 unless action is taken immediately to forestall such an event.22 There are two major categories of weapons about which they are most concerned. Obviously, nuclear weapons in the hands of terrorists could kill enormous numbers of people, and the Commission agrees that the risk of a nuclear terrorist attack is increasing. However, they predict that it is more likely that terrorists will obtain and use a biological weapon first.23... 

FDA has responded to the threat of terrorism with a unique approach towards the development of biopharmaceuticais intended to counter the adverse effects of chemical, biological, radiological, or nuclear substances [83]. In many instances, efficacy trials in humans cannot be ethically performed (e.g., anti-bioterrorism agents). In these instances, animal data can be used in place of human data to model the in-vivo pharmacodynamics. In particular, studies in animals can provide substantial evidence of the effectiveness of biopharma-ceutical products intended for possible use to reduce or prevent the toxicities of these agents under defined circumstances. Such studies should be conducted under GLP (21 CFR 58) and are appHcable when ... 

---